♥️Meds for HCM very limited and don't prevent progression or reverse it
♥️HCM results from too many cross bridging and this drug prevents this
#EXPLORER #ESCCongress
![](https://pbs.twimg.com/media/Egl5-8CWoAIrNFN.jpg)
![](https://pbs.twimg.com/media/Egl5-8BXcAEvSoO.jpg)
![](https://pbs.twimg.com/media/Egl5-8AXkAAvtBP.jpg)
Study & Characteristics &Results as below:
🔺251 Patients (largest trial in HCM)
🔺97% completed study
🔺Improved functional score and improved NYHA class
🔺⬇️post exercise gradients
🔺⬇️ resting and valsalva gradient
![](https://pbs.twimg.com/media/Egl6Zo8XsAI0QzD.jpg)
![](https://pbs.twimg.com/media/Egl6dFRXYAIwv0S.jpg)
![](https://pbs.twimg.com/media/Egl6hrxWsAA23y4.jpg)
![](https://pbs.twimg.com/media/Egl6hr1X0AAKZsf.jpg)
#ESCCongress
🔺Complete response in 27% as what is seen in septal myomectomy
🔺Very safe & well tolerated drug
🔺Question if beta blockers poorly tolerated in HCM & perhaps time to get rid of this as a med in HCM
![](https://pbs.twimg.com/media/Egl7c93XcAEI-CI.jpg)
![](https://pbs.twimg.com/media/Egl7c95WAAEyhv7.jpg)
![](https://pbs.twimg.com/media/Egl7c94WkAIarYR.jpg)
![](https://pbs.twimg.com/media/Egl7c96WAAY1ahg.jpg)
📌75% of HCM patients saw a reduction in LVOT gradients
📌Need longterm data to know if effect on SCD & 56% had complete relief of symptoms
📌#Mavacamten very well tolerated & improved functional capacity
Is it time for this drug? Or need more data?
![](https://pbs.twimg.com/media/Egl8T25XYAEdG8J.jpg)